Liquidia (LQDA) Cash from Financing Activities (2020 - 2026)

Liquidia's (LQDA) quarterly Cash from Financing Activities came in at -$18.1 million in Q1 2026, down 174.33% year-on-year from $24.3 million in Q1 2025, and down 157.11% quarter-over-quarter from -$7.0 million in Q4 2025.

Liquidia (LQDA) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Liquidia's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$18.1 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 174.33% year-over-year to -$18.1 million in Q1 2026; TTM through Mar 2026 was $17.4 million, a 85.43% decrease from a year earlier, with the FY2025 full-year figure at $59.7 million, down 69.32% from the prior year.
  • Cash from Financing Activities fell to -$18.1 million in Q1 2026 per LQDA's latest filing, from -$7.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $99.7 million in Q1 2024 and bottomed at -$18.1 million in Q1 2026.
  • The 5-year median for Cash from Financing Activities is $10.0 million (2023), against an average of $20.3 million.
  • Across the five-year window, Cash from Financing Activities surged 41377.19% in 2023 and tumbled 205.84% in 2025, its largest moves.
  • Year by year, Cash from Financing Activities stood at $57000.0 in 2022, then jumped by 41377.19% to $23.6 million in 2023, then plunged by 109.71% to -$2.3 million in 2024, then tumbled by 205.84% to -$7.0 million in 2025, then tumbled by 157.11% to -$18.1 million in 2026.
  • Per Business Quant, the three latest LQDA Cash from Financing Activities figures stand at -$18.1 million (Q1 2026), -$7.0 million (Q4 2025), and -$5.2 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 13.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -840.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -494.13 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1.48 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -203.80 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -86.10 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -65.00 Mn
10 Liquidia 7.84 Bn 7.61 Bn 121.79 Mn -18.05 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -18.05 Mn
Mar 31, 2026 -18.05 Mn
Dec 31, 2025 -7.02 Mn
Dec 31, 2025 -7.02 Mn
Sep 30, 2025 -5.25 Mn
Sep 30, 2025 -5.25 Mn
Jun 30, 2025 47.71 Mn
Jun 30, 2025 47.71 Mn
Mar 31, 2025 24.29 Mn
Mar 31, 2025 24.29 Mn
Dec 31, 2024 -2.30 Mn
Dec 31, 2024 -2.30 Mn
Sep 30, 2024 98.10 Mn
Sep 30, 2024 98.10 Mn
Jun 30, 2024 -814,000.00
Jun 30, 2024 -814,000.00
Mar 31, 2024 99.67 Mn
Mar 31, 2024 99.67 Mn
Dec 31, 2023 23.64 Mn
Dec 31, 2023 23.64 Mn